(Q31861860)

4 July 2017

title

Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. (English)

1 reference

4 July 2017

0 references

J Lavalaye

1

1 reference

4 July 2017

D H Linszen

2

1 reference

4 July 2017

J Booij

3

1 reference

4 July 2017

P M Dingemans

4

1 reference

4 July 2017

L Reneman

5

1 reference

4 July 2017

J B Habraken

6

1 reference

4 July 2017

B P Gersons

7

1 reference

4 July 2017

E A van Royen

8

1 reference

4 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

4 July 2017

published in

Schizophrenia Research

1 reference

4 July 2017

volume

47

1 reference

4 July 2017

issue

1

1 reference

4 July 2017

page(s)

59-67

1 reference

A rating scale for drug-induced akathisia

4 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

[3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Dopamine in schizophrenia: a review and reconceptualization

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

[3H]GBR-12935 binding sites in human striatal membranes: binding characteristics and changes in parkinsonians and schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

[123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Provocative tests with psychostimulant drugs in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Elevated dopa decarboxylase activity in living brain of patients with psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Brain dopamine transporter: gender differences and effect of chronic haloperidol.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Psychopathology in women and men: focus on female hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

The vesicular monoamine transporter is not regulated by dopaminergic drug treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900023-2

7 January 2021

10.1016/S0920-9964(00)00023-2

Identifiers

DOI

1 reference

4 July 2017

1 reference